Judge Allows Drug Battle Over TriCor To Proceed

Law360, New York (June 1, 2006, 12:00 AM EDT) -- In the latest in a long-running battle between pharmaceutical companies over generic versions of the cholesterol drug TriCor, a judge has ruled that a pending antitrust case against Abbott Laboratories can proceed.

Attorneys for Abbott Laboratories and Fournier Industrie et Sante asked Judge Kent Jordan to dismiss a lawsuit alleging that they manipulated antitrust laws to keep a generic equivalent of TriCor, or Fenofibrate, off the market.

Abbott markets TriCor in the U.S. for French drug maker Fournier.

Jordan dismissed the drug companies' arguments in a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.